Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
83 Leser
Artikel bewerten:
(0)

AstraZeneca and Grace Hill Neighborhood Health Centers, Inc. Provide Medicines to Missouri's Uninsured

WILMINGTON, Del., July 21 /PRNewswire-FirstCall/ -- AstraZeneca announced today that it is providing medicines at no cost to qualifying patients at Grace Hill Neighborhood Health Centers, Inc. in St. Louis.

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

AstraZeneca's partnership with Grace Hill is an expansion of its AZ&Me(TM) Prescription Savings program that provides medicines at no cost to health facilities around the country. Grace Hill is the sixth facility in Missouri to join the program.

For more than 100 years, Grace Hill has provided primary and preventive healthcare in St. Louis. In 2009, Grace Hill provided health services to more than 41,000 patients at its six health center locations in St. Louis. Nearly 60 percent of these patients did not have health insurance, and more than 90 percent had incomes under the federal poverty level.

"At Grace Hill Neighborhood Health Centers, our mission is to serve our neighbors by providing high quality healthcare," said Alan O. Freeman, Grace Hill president and CEO. "Working with AstraZeneca will help us reduce costly access barriers facing many of our patients today."

The local chapter of the National Alliance on Mental Illness (NAMI) praised the collaboration, saying the resources available at Grace Hill are of critical importance to patients.

"With the downturn in the economy, NAMI's HelpLine has been receiving an increase in calls from people who are uninsured," said Jacqueline Lukitsch, executive director at NAMI in St. Louis. "It is good to know that NAMI will be able to refer uninsured patients to Grace Hill for treatment and patient assistance."

In 2009, AstraZeneca provided more than $15.2 million in savings to more than 11,190 patients in Missouri under its prescription savings programs - known as AZ&Me. Nationally, the company helped more than 507,000 patients save $679.6 million on their medicines.

"Working together, we will help Missourians access the medicines they need," said Jennifer McGovern, director, patient assistance programs, AstraZeneca Pharmaceuticals LP. "AstraZeneca is dedicated to improving the health of our communities by collaborating with organizations that share our commitment to patients."

About AZ&Me Prescription Savings Program for Healthcare Facilities

AZ&Me(TM) Prescription Savings program for healthcare facilities provides medicines free of charge to community free clinics, community health centers, hospitals and other qualifying facilities that serve the uninsured. The program is available to non-profit organizations that have a licensed outpatient pharmacy or dispensary on site and meet other program criteria. Patients are eligible for AstraZeneca medicines through this program if they do not have prescription drug coverage and have a household income at or below $30,000 for an individual or $60,000 for a family of four.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit http://www.astrazeneca-us.com/ or call 1-800-AZandMe (292-6363).

Photo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO
PRN Photo Desk, photodesk@prnewswire.com
http://photos.prnewswire.com/prnh/20091027/PH99766LOGO

AstraZeneca

CONTACT: Steve Hahn of AstraZeneca Pharmaceuticals LP, +1-302-885-4762;
or Gerald Sonnenberg of Grace Hill Neighborhood Health Centers, Inc.,
+1-314-814-8774

Web Site: http://www.astrazeneca-us.com/

© 2010 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.